[Market Focus] Tomocube Surges Over 6% After First Quarterly Profit

The share price of Tomocube, which has posted its first operating profit since its founding, is on the rise.

As of 9:45 a.m. on the 9th, Tomocube was trading at 58,600 won, up 3,400 won (6.16%) from the previous trading day.

On this day, Choi Seunghwan, a researcher at Shinhan Investment & Securities, said of Tomocube, "In the fourth quarter of last year, the company achieved sales of 5 billion won (up 449.1% year-on-year) and an operating profit of 400 million won, successfully returning to the black," adding, "With 44% of annual sales concentrated in the fourth quarter alone, the company proved its order-winning competitiveness with pharmaceutical companies and research institutions."

This year, earnings growth is expected to be driven by the global expansion of adoption of its flagship equipment, the "HT-X1," and the launch of the next-generation equipment, the "HT-X1 Max." The next-generation HT-X1 Max is currently undergoing work to standardize AI-based organoid (artificial organ) phenotype analysis in collaboration with major global pharmaceutical companies.

Researcher Choi stressed, "Medical artificial intelligence (AI) companies tend to see their share prices rapidly re-rated from the moment they prove their profitability," adding, "It is one of the companies that deserves the most attention this year."